Table 1 Baseline characteristics of patients with and without left ventricular reverse remodeling (LVRR)

Female,n(%)

9(19.6)

14(24.6)

0.545

Age(years)

44.2 ± 14.6

50.2 ± 14.7

0.042

BMI(kg/m²)

26.6 ± 4.5

25.5 ± 4.9

0.232

NYHA functional class>II,n(%)

28(60.9)

32(56.1)

0.628

Medical history, n(%)

Hypertension

27(58.7)

30(52.6)

0.538

Hyperlipidemia

10(21.7)

6(10.5)

0.118

Diabetes mellitus

12(26.1)

9(15.8)

0.197

Atrial fibrillation

2(4.3)

9(15.8)

0.122

Vital singns

HR(bpm)

91.8 ± 13.9

83.9 ± 16.4

0.011

SBP(mmHg)

124.3 ± 23.9

123.4 ± 20.9

0.845

DBP(mmHg)

80.5(73.0-96.3)

80.0(67.0–88.0)

0.291

Treatments, n (%)

ACEI/ARB/ARNI

40(87.0)

51(89.5)

0.692

Beta-blocker

41(89.1)

54(94.7)

0.492

Aldosterone antagonist

43(93.5)

55(96.5)

0.806

Loop diuretic

42(91.3)

48(84.2)

0.281

SGLT2i

5(10.9)

3(5.3)

0.492

Digoxin

8(17.4)

15(26.3)

0.280

Laboratory data

TG(mmol/L)

1.4(1.1–1.8)

1.1(0.9–1.6)

0.005

TC(mmo/L)

4.3 ± 0.9

4.2 ± 1.0

0.639

HDL-C(mmol/L)

0.9 ± 0.3

1.0 ± 0.3

0.198

LDL-C(mmo/L)

2.6 ± 0.7

2.6 ± 0.8

0.713

Fasting plasma glucose(mmol/L)

5.0(4.6–6.1)

4.9(4.3–5.5)

0.065

C-reactive protein(mg/L)

3.8(2.7–5.7)

4.2(2.5–5.9)

0.832

Creatinine(μmol/L)

77.7(66.9–85.1)

81.0(59.5–92.7)

0.559

Hb(g/L)

148.4 ± 19.4

144.8 ± 20.4

0.367

BNP(pg/mL)

517.0(308.7-933.8)

672.0(223.0-1160.0)

0.434